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Alcohol use disorders (AUDs) have a staggering socioeconomic impact. Few therapeutic
options are available, and they are largely inadequate. These shortcomings highlight the
urgent need to develop effective medications to prevent and/or treat AUDs. A critical
barrier is the lack of information regarding the molecular target(s) by which ethanol
(EtOH) exerts its pharmacological activity. This review highlights findings implicating P2X4
receptors (P2X4Rs) as a target for the development of therapeutics to treat AUDs and
discusses the use of ivermectin (IVM) as a potential clinical tool for treatment of AUDs.
P2XRs are a family of ligand-gated ion channels (LGICs) activated by extracellular ATP. Of
the P2XR subtypes, P2X4Rs are expressed the most abundantly in the CNS. Converging
evidence suggests that P2X4Rs are involved in the development and progression of AUDs.
First, in vitro studies report that pharmacologically relevant EtOH concentrations can
negatively modulate ATP-activated currents. Second, P2X4Rs in the mesocorticolimbic
dopamine system are thought to play a role in synaptic plasticity and are located
ideally to modulate brain reward systems. Third, alcohol-preferring (P) rats have lower
functional expression of the p2rx4 gene than alcohol-non-preferring (NP) rats suggesting
an inverse relationship between alcohol intake and P2X4R expression. Similarly, whole
brain p2rx4 expression has been shown to relate inversely to innate 24 h alcohol
preference across 28 strains of rats. Fourth, mice lacking the p2rx4 gene drink more
EtOH than wildtype controls. Fifth, IVM, a positive modulator of P2X4Rs, antagonizes
EtOH-mediated inhibition of P2X4Rs in vitro and reduces EtOH intake and preference
in vivo. These findings suggest that P2X4Rs contribute to EtOH intake. The present review
summarizes recent findings focusing on the P2X4R as a molecular target of EtOH action,
its role in EtOH drinking behavior and modulation of its activity by IVM as a potential
therapy for AUDs.
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INTRODUCTION
Alcohol use disorders (AUDs) rank third on the list of pre-
ventable causes of morbidity and mortality in the United States,
having a major national impact that affects over 18 million peo-
ple and causes over 100,000 deaths annually (Grant et al., 2004;
Johnson, 2010; Bouchery et al., 2011). The economic burden
to society for AUDs is in excess of $220 billion/year (Bouchery
et al., 2011) which exceeds the costs of other leading preventable
causes of death such as cigarette smoking and physical inactivity
(Naimi, 2011). To compound this dire scenario, few therapeu-
tic options for AUDs are available, and are largely inadequate
(Johnson, 2010). These factors highlight the urgent need for the
development of new, effective medications to prevent and/or treat
alcohol abuse and dependence (Heilig and Egli, 2006; Johnson
et al., 2007; Steensland et al., 2007).
Drug development for AUDs is a relatively young field, com-
pared to other diseases such as cancer, cardiovascular, and psychi-
atric disorders (Litten et al., 2012). At the present time, the only
pharmacotherapeutic agents approved by the FDA for the treat-
ment of AUDs are disulfiram (Antabuse®), naltrexone (Revia®
and Vivitrol®), and acamprosate (Campral®), with Vivitrol®
being an extended-release injectable formulation of naltrexone
(Harris et al., 2010; Litten et al., 2012). These drugs attempt to
deter alcohol intake by blocking its metabolism or by targeting the
neurochemical and neuropeptide systems that lead to craving and
dependence (Gewiss et al., 1991; Colombo et al., 2007; Steensland
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et al., 2007; Johnson, 2010; Litten et al., 2012). These traditional
approaches, even in combination with psychological strategies,
have had limited success. The continuing high rates of alcohol
abuse coupled with the failure of current treatment strategies have
led to considerable effort directed toward the development of
new drugs to treat alcohol abuse and dependence (Johnson, 2010;
Litten et al., 2012). However, a critical barrier in this endeavor
is the lack of information regarding the molecular target(s) by
which alcohol exerts its pharmacological activity.
ION CHANNELS ARE IMPORTANT TARGETS OF ETHANOL
ACTION
Ligand-gated ion channels (LGICs) are widely held to play
an important role in ethanol-induced behaviors and drinking
(Deitrich et al., 1989; Weight et al., 1992; Dildy-Mayfield et al.,
1996; Mihic et al., 1997; Cardoso et al., 1999; Harris, 1999;
Woodward, 2000; Davies and Alkana, 2001). Research in this area
has focused on investigating the effects of ethanol on two large
“superfamilies” of LGICs: (1) The nicotinic acetylcholine recep-
tor superfamily (cys-loop) with members including nicotinic
acetylcholine receptors (nAChRs), 5- hydroxytryptamine type
3 receptors (5-HT3Rs), γ-aminobutyric acid type-A receptors
(GABAARs) and glycine receptors (GlyRs) (Betz, 1990; Ortells
and Lunt, 1995) and (2) the glutamate superfamily (Monaghan
et al., 1989; Sommer et al., 1992).
OVERVIEW OF PURINERGIC RECEPTORS
Within the mammalian CNS, two major purinergic recep-
tor families that bind adenine nucleotides including adenosine
5′-triphosphate (ATP), consisting of the P2X family of LGICs and
the P2Y family of G protein-coupled receptors (Burnstock et al.,
2011). In addition to binding ATP, the P2Y receptor class also
binds adenosine 5′-diphosphate (ADP) as well as uridine nucleo-
sides and nucleotides. A third member of this neurotransmitter
class, termed P1, binds adenosine and includes the adenosine
receptors A1, A2a, A2b, and A3. Structurally, the P2X and P2Y
families are composed of 7 and 8 unique subunits (Coddou et al.,
2011), respectively, and are widely expressed in a number of
distinct regions within the CNS (Soto et al., 1997).
Thus, purinergic P2X receptors (P2XRs) form functional
heteromeric or homomeric receptors (Coddou et al., 2011).
Presynaptic P2XRs modulate the release of other neurotrans-
mitters which may be co-released with ATP (Burnstock, 2004;
Khakh and North, 2006). Due to the high calcium permeability of
these receptors, researchers also have indicated that post-synaptic
P2XRs modulate synaptic transmission and interneuronal signal-
ing (Khakh and North, 2006; Jarvis and Khakh, 2009). Since the
focus of this review is primarily on the P2X4 receptor (P2X4R)
and its role in alcohol drinking behavior, this receptor will be
discussed in light of its distribution, expression levels, and phys-
iological roles in modulating neurotransmission in those circuits
of the brain known to regulate these behaviors.
While much of our understanding of the P2X4R is derived
from its cloning and expression in the rat and mouse (Bo et al.,
1995), the human ortholog, termed hP2X4, has been cloned and
shares 87% sequence identity with the rat polypeptide (Garcia-
Guzman et al., 1997). Structurally, the P2X4R channel is arranged
as a trimeric complex at the cell membrane and functions as a
LGIC for both monovalent (Na+ and K+) and divalent (Ca2+)
cations. In fact, at resting potentials, P2X4Rs are able to flux
high Ca2+ concentrations, at levels approaching or exceeding
those of the N-methyl-D-aspartate (NMDA) subtype of glutamate
receptor (Abbracchio et al., 2009). Since the NMDA receptor is
blocked by Mg2+ ions at resting potentials, P2X4Rs as well as
other P2XRs, may play an important role in synaptic plasticity
potentially complementing the regulatory role of the α-Amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of
glutamate receptor (Kessels and Malinow, 2009). Several reports
suggest that P2X4Rs contribute to the induction of hippocampal
long-term potentiation (LTP), and possibly long-term depression
(LTD), directly influencing synaptic strength (Cunha et al., 1996;
Cunha and Ribeiro, 2000; Yamazaki et al., 2003; Fujii, 2004).
For example, mice lacking the p2rx4 gene (P2X4-KO) displayed
reduced induction of LTP (Sim et al., 2006). Therefore, P2X4Rs
themselves may play a role in maintaining homeostatic plastic-
ity and influencing the threshold for LTP and LTD induction
(Pankratov et al., 2002).
Both in situ hybridization histochemistry and immunohisto-
chemical staining [light and electron microscopy (EM) immuno-
gold labeling] in conjunction with western immunoblotting have
demonstrated that P2XRs are distributed widely within the mam-
malian CNS in a heterogeneous fashion. P2X4Rs, along with
P2X2Rs and P2X6Rs, are the most robustly expressed functional
ATP-gated purinergic receptors in the CNS (e.g., Khakh, 2001;
Amadio et al., 2007; Surprenant and North, 2009; Coddou et al.,
2011), and are found on most neurons and glial cells (Burnstock
and Knight, 2004; Ulmann et al., 2008; Choi et al., 2009). The
P2X4Rs are localized in the hippocampal pyramidal layers CA1,
CA2, and CA3 as well as the granule layers of the dentate gyrus,
Purkinje cells of the cerebellum, the cerebral cortex including
both somatosensory and prefrontal regions, the medial habenula,
olfactory bulb, and spinal cord (Bo et al., 1995; Buell et al., 1996;
Kanjhan et al., 1999; Rubio and Soto, 2001). Analysis with EM
immunostaining suggests that P2X4Rs are preferentially localized
to the post-synaptic terminal, predominantly toward the periph-
ery of the synapse (Rubio and Soto, 2001). However, additional
studies have suggested that P2X4Rs are localized to both the
pre-synaptic as well as post-synaptic terminal in several brain
regions (Rubio and Soto, 2001; Burnstock et al., 2011). Based
on physiological studies, P2X4Rs can form homo-multimeric
complexes with themselves or hetero-multimeric assemblies with
P2X6, for example (Torres et al., 1999). Recent studies map-
ping P2X4R expression have now identified co-localization of
these receptors within dopaminergic neurons within the sub-
stantia nigra pars compacta (SNpc) as well as GABAergic neu-
rons in both the striatum and substantia nigra pars reticulate
(SNpr) (Amadio et al., 2007). Administration of ATP to the
dopaminergic neurons of the SNpc can modulate firing activ-
ity as well as the release of presynaptic dopamine (Choi et al.,
2009). Similar regulation of dopamine release in the nucleus
accumbens (NAc) has also been reported (Krugel et al., 2003).
In addition to normal levels of expression, the P2X4R has been
reported to be altered by dopamine depletion, specifically the 6-
hydroxydopamine rat model of Parkinson’s disease, resulting in
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decreased expression in the SNpc and dorsal striatal GABAergic
neurons, and increased expression in SNpr GABAergic neurons
(Amadio et al., 2007). Taken together these findings support
a close relationship between P2X4R expression and dopamine
neurotransmission.
The close relationship between the P2X4R and alcohol drink-
ing behavior is supported by the localization of P2X4Rs within
the reward circuitry of the mammalian brain (Figure 1), specif-
ically the mesolimbic and mesocortical pathways that consist of
connections originating in the ventral tegmental area (VTA) of
the midbrain, connecting to the NAcc (also termed the ventral
striatum), amygdala, limbic system, hippocampus, and prefrontal
cortex (Gonzales et al., 2004). Within this circuitry, P2X4Rs have
been localized to these regions either within neurons (Rubio
and Soto, 2001) or glia (both microglia and astrocytes) (Rubio
and Soto, 2001; Ulmann et al., 2008, 2013), implicating a role
in reward- and aversion-related neurotransmission, as well as
cellular immune activity. Functional studies also have reported
that P2X4Rs can play an important role in the reward cir-
cuitry by regulating the release of glutamate (Krugel et al., 2004;
Khakh, 2009) or dopamine (Krugel et al., 2003; Kittner et al.,
2004) within the VTA and NAcc. In addition, the identifica-
tion of ATP as a co-neurotransmitter in both glutamatergic and
dopaminergic neurons strongly implicates the role of P2X4Rs
and other purinergic receptor signaling in synaptic transmission
as well as synaptic plasticity within these regions (Krugel et al.,
2003).
Neuronal and glial P2X4Rs and other P2XRs regulate neuro-
transmission directly. They also may be involved in a number
of distinct mechanisms influencing synaptic plasticity within
the reward circuitry, thus influencing alcohol-drinking behav-
iors. For example, the expression and utilization of neurotrophic
factors such as brain-derived neurotrophic factor (BDNF) (Trang
et al., 2009; Klein et al., 2012) and nerve growth factor (NGF)
(D’Ambrosi et al., 2001) can modulate synaptic plasticity by
modulating LTP induction. It is well-accepted that neuro-
inflammatory processes play both deleterious and beneficial roles
in synaptic plasticity and cell death (Wee, 2010). The fact that
P2X4Rs are localized in microglia suggests that these receptors
may regulate the activation, migration, cytokine release, and
physiological roles of microglia at sites of neuroplasticity, includ-
ing injury (Tsuda et al., 2003; Sim et al., 2007). It is not yet
known if these regulatory processes through microglia lead to the
loss of synaptic connectivity or play a regulatory role to enhance
synaptic strength. ATP levels also can be regulated enzymati-
cally through expression of ecto-nucleotidases thus influencing
purinergic receptor activity such as seen in the hippocampus
in models of learning (Bonan et al., 2000; Rucker et al., 2004).
Finally, P2X4Rs have been reported to modulate signaling in a
wide spectrum of LGICs including those receptors for GABAA,
glycine, nicotinic acetylcholine, and glutamate demonstrating its
wide and complex sphere of influence (Adelsberger et al., 2000;
Andries et al., 2007; Sattelle et al., 2009; Tabakoff et al., 2009;
Baxter et al., 2011).
Activation of these LGIC receptors has been reported to medi-
ate some of ethanol’s behavioral effects (Grant, 1994). The mod-
ulatory interaction of P2X4Rs with these other ethanol-related
receptor families likely is indicative of an indirect association
between P2X4Rs and some of the molecular actions of ethanol.
In addition, growing evidence supports a more direct interac-
tion between P2X4Rs and the effects of ethanol. Alcohol drinking
and abuse behaviors sharemany similarities with addictive behav-
iors to drugs of abuse such as cocaine. Purinergic receptors such
as P2X4Rs are in a position to influence reward and aversive
FIGURE 1 | The major connections within the reward and aversion
circuitry are regulated by P2X4Rs either directly or indirectly.Within these
neuroanatomical regions P2X4Rs either colocalized to neuronal cell bodies or
localized to glia and modulate the release of various neurotransmitters. Major
neurotransmitters and their pathways include (i) dopamine (black dash) linking
the VTA with the NAcc (ventral striatum), PFC, and hippocampus; (ii) glutamate
(blue line), an important neurotransmitter linking the PFC to the NAcc, striatum,
and VTA, as well as between the LHab and VTA, hippocampus and NAcc, and
Amyg and NAcc; and GABA (red line) between the NAcc and SNpc or GP.
Abbreviation: Amyg, amygdala; Cbm, cerebellum; GP, globus pallidus; LHab,
lateral habenular; NAcc, nucleus accumbens; PFC, prefrontal cortex; SN,
substantia nigra; Str, striatum; VTA, ventral tegmental area.
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circuits especially those involving dopamine thus implicating
this class of receptors in modulation of synaptic signaling asso-
ciated with addictions. Therefore, the P2X4R may serve as an
important therapeutic target in treating alcohol abuse behaviors
(Davies et al., 2005; Asatryan et al., 2011; Litten et al., 2012).
This line of research is further supported by the direct demon-
stration of interactions with ethanol on P2X4Rs and the fact that
drugs that potentiate P2X4R neurotransmission such as IVM can
reverse some of ethanol’s behavioral effects (Davies et al., 2005;
Ostrovskaya et al., 2011).
ETHANOL INHIBITS THE FUNCTION OF P2X4Rs
To date, P2X4Rs are the most ethanol-sensitive P2XR subtype
tested. Findings indicate that intoxicating and anesthetic ethanol
concentrations desensitize the response of P2X4R-expressing cell
lines to ATP exposure (Li et al., 1993; Xiong et al., 2000; Davies
et al., 2002, 2005; Ostrovskaya et al., 2011), altering the ability
of these receptors to modulate neurotransmission. Initial voltage
clamp studies in the late 1990’s, testing rat recombinant homo-
meric P2X4Rs expressed in Xenopus oocytes found that ethanol
caused concentration-dependent inhibition of ATP-induced cur-
rents with the IC50 determined at 58mM (Xiong et al., 2000).
Caution must be taken when interpreting the IC50 value in this
study (Xiong et al., 2000) as it was determined by testing a
range of ethanol concentrations from 1 to 500mM. Later stud-
ies using two-electrode voltage clamp confirmed the inhibitory
effects of ethanol in rat P2X4Rs, but focused on lower concen-
trations (25–200mM) (Davies et al., 2002, 2005; Asatryan et al.,
2010). The extent of ethanol inhibition was 50–60% at 200mM.
Notably, the inhibitory effects of ethanol on ATP-gated P2X4R
function were not dependent on the expression or recording sys-
tem as similar results were found when tested in frog oocytes,
transfected HEK293 cells, and lentivirally transduced mouse hip-
pocampal neurons (Ostrovskaya et al., 2011). Ethanol-induced
P2X4R inhibition may provide some insight regarding the role
of P2X4Rs in ethanol intake (described below) (Li et al., 1998;
Weight et al., 1999; Xiong et al., 2000; Davies et al., 2005).
THE P2X4R MECHANISM OF ETHANOL INHIBITION
Recent investigations from two-electrode voltage clamp and
patch clamp studies demonstrate that ethanol inhibition of ATP-
activated currents in P2X4Rs is not dependent on membrane
potential (from −60 to +20mV), and ethanol does not change
the reversal potential of ATP-activated current (Xiong et al., 2005;
Ostrovskaya et al., 2011). This work argues that ethanol does not
affect the receptor function directly, but rather act as a negative
allosteric modulator as illustrated by its ability to shift the ATP
concentration response curve to the right and increase the EC50
value significantly (Davies et al., 2002, 2005).
Earlier investigations suggested that ethanol might inhibit
P2X4Rs by decreasing the apparent affinity of the binding site for
ATP (Xiong et al., 2005). However, recent studies using patch-
clamp and a HEK 293 expression system provided more insights
into the intricate mechanisms of ethanol action in P2X4Rs
(Ostrovskaya et al., 2011). In this latter study, the authors reported
that there was no difference in the magnitude of ethanol inhibi-
tion at a wide range of ATP concentrations, which contradicted
the previous findings that a more prominent effect was present at
the lower end of the tested ethanol concentrations (Ostrovskaya
et al., 2011). The observation that there was no change in chan-
nel deactivation supported the recent findings. These studies also
demonstrated that ethanol interaction with P2X4Rs is rapid with
very fast rates of association and dissociation (Ostrovskaya et al.,
2011). Moreover, the findings suggested a use-dependent mech-
anism for the action of ethanol consistent with properties of an
open-channel blocker. Interestingly, in contrast to classic open-
channel blockers, ethanol did not stabilize the open/desensitized
states of the channel and did not change the ion permeability
ratio. These properties are consistent with a low-affinity modu-
lator “binding,” which is a dynamic series of on and off bounces
in the putative binding sites or interaction pockets.
SITES OF ETHANOL ACTION IN P2X4Rs
Knowledge regarding the molecular targets of ethanol in P2X4Rs
remains limited. Site directed mutagenesis as well as chimeric
construction strategies have been used to look into the impor-
tant molecular sites for the action of ethanol in P2XRs. Earlier
work from the Davies lab that used a chimeric construction
approach between P2X2 and P2X3 receptor subunits found that
the interface between the transmembrane (TM) segments and the
ectodomain, as well as the TM segments themselves, are impor-
tant for the actions of ethanol (Asatryan et al., 2008). These
studies were extended to P2X4Rs where an alanine scan of the
indicated regions was performed via site-directed mutagenesis
(Popova et al., 2010). The studies identified two residues at the
ectodomain-TM2 interface, i.e., Asp331 and Met336, that when
mutated to alanine significantly reduced ethanol inhibition of
ATP-gated currents (Popova et al., 2010). Interestingly, Asp331
mutations affected ethanol sensitivity at higher ethanol concen-
trations (>50mM), whereas Met336 mutations were sensitive to
lower, intoxicating ethanol concentrations (10mM). These muta-
tions did not cause significant changes in the agonist response,
i.e., ATP Imax, EC50, or Hill slope. More detailed study of the
physico-chemical properties of these identified sites using the
mutagenesis approach and correlation analyses revealed a signifi-
cant relationship between the ethanol response and hydropathy
as well as polarity, but not the molecular volume/molecular
weight of the residues at these two positions (Popova et al.,
2010). Further patch clamp studies focusing on the identified
residues confirmed that they are involved in ethanol inhibition
(Ostrovskaya et al., 2011). In addition, these studies suggested
that Met336 and Asp331 play a role in P2X4R gating.
The involvement of Asp331, Met336 in an action pocket for
ethanol was confirmed later on the first molecular model of the
rat P2X4R (Asatryan et al., 2010). This model also demonstrated
that Trp46 in the TM1 segment of the receptor contributed to the
formation of the putative binding pocket. The important role of
Trp46 in these molecular interactions was later supported exper-
imentally (Popova et al., 2013). Alanine substitution at position
46, but not at any other positions of the TM1 segment, abolished
ethanol inhibition of P2X4Rs (Popova et al., 2013). Importantly,
the presence of an aromatic ring at position 46 appeared to be
required for the maximal response to ethanol. Notably, as with
Asp331 the reduction of ethanol inhibition was found at higher
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ethanol concentrations (≥50mM). These findings are relevant
to chronic alcohol abusers whose blood ethanol concentrations
generally reach levels as high as 50mM and above. The find-
ings also supported the notion that there are multiple sites for
ethanol action in P2X4Rs—(1) high affinity sites (such as position
336) that are sensitive to lower intoxicating concentrations expe-
rienced by most social drinkers and (2) low affinity sites (such as
positions 46 and 331) that display responses at the higher con-
centrations achieved by chronic alcoholics. Taken together, these
findings suggest that there is a direct interaction of ethanol with
P2X4Rs, which may have important implications for the role of
these receptors in AUDs. This suggestion is supported by P2X4R
populations in central areas that promote alcohol drinking.
CURRENT IN VIVO SUPPORT FOR INVOLVEMENT OF P2X4Rs
IN ALCOHOL DRINKING
As presented above, P2XRs have been associated regionally and
functionally with several CNS areas implicated in with ethanol
consumption and reinforcement (Krugel et al., 2003; Amadio
et al., 2007; Heine et al., 2007). For example, evidence sug-
gests that dense P2X4R populations on medium spiny neurons,
interneurons, and microglia in the VTA may modulate ethanol-
induced changes to GABA and glutamate neurotransmission and
dopamine levels in the NAcc (Xiao et al., 2008). These areas are
highly related to the regulation and reinforcing effects of ethanol
and other drugs of abuse (Pierce and Kumaresan, 2006) and dis-
ruptions in these areas may contribute to the development of
AUDs. Moreover, the high expression of P2X4Rs in these areas
may suggest that these receptors are involved in the some of the
behavioral, cellular, and molecular effects of ethanol (Pankratov
et al., 2009; Tabakoff et al., 2009).
In addition, regional differences in P2X4R levels may be
involved in innate alcohol preference. Several research groups
have used gene expression profiling to demonstrate differences
in p2rx4 mRNA in animals genetically selected for divergent
ethanol intake. First, Kimpel et al. (2007) reported that p2rx4
mRNA was reduced in composite preparations of five brain
regions from inbred alcohol-preferring (iP) rats, relative to their
non-preferring (iNP) counterparts. Second, reduced p2rx4 lev-
els were found in the VTA of male alcohol-preferring (P) vs.
-non-preferring (NP) and high alcohol drinking vs. low alcohol
drinking (HAD1/LAD1) rats (McBride et al., 2012). Interestingly,
these researchers reported that p2rx4 expression was increased
in a replicate high-alcohol drinking (HAD2) rat line, relative to
its low-alcohol drinking (LAD2) counterparts (McBride et al.,
2012). Taken together, evidence suggests that disparate p2rx4
gene expression contributes to high alcohol drinking phenotypes.
Further, these findings highlight the significance of genetic het-
erogeneity in developing medications for the treatment of AUDs
and emphasize the importance that pharmacogenetics likely will
play in future medications development (Johnson, 2010; Heilig
et al., 2011).
The above studies were conducted in ethanol-naïve subjects
with a genetic propensity to consume large quantities of alco-
hol. In line with these findings, growing evidence from pre-
clinical animal models suggests that functional differences in
P2X4Rs manifest behaviorally in altered alcohol drinking levels.
Tabakoff et al. (2009) found that lower levels of whole brain
expression of p2rx4 mRNA in inbred rats were associated with a
high ethanol-drinking phenotype compared to those with a lower
ethanol-drinking phenotype. Simply put, expression of p2rx4 was
negatively correlated with 24-h two-bottle free choice alcohol
intake. In agreement with this finding, male P2X4-KO mice dis-
played increases in 10% ethanol intake under intermittent 4-h
limited access conditions, and under 24-h access conditions, rel-
ative to wild-type (WT) mice (Wyatt et al., 2014). Furthermore,
in the same report (Wyatt et al., 2014), it was found that acqui-
sition of 24-h, two-bottle choice alcohol (vs. water) drinking
occurred earlier in male P2X4-KO mice, compared to WT con-
trols. As P2X4R-KOmice display differences in ethanol intake and
some of the sedative-hypnotic properties of ethanol, as well as
exhibiting elevations in GABAAR expression in the cerebellum,
relative to WT mice (Wyatt et al., 2014), it is possible that one
role for P2X4Rs is to regulate some of ethanol’s GABA-mediated
behavioral effects.
This suggestion is in line with the ability of P2X4Rs to
modulate GABA neurotransmission and may indicate that these
receptors are involved in GABA-mediated regulation of ethanol
consumption (Rewal et al., 2009). However, it has been difficult to
develop an efficacious clinical assessment for the direct involve-
ment of P2X4Rs in the human alcoholic condition. Therefore,
selective pharmacological agents that target P2X4Rs have been
utilized in several pre-clinical laboratory studies to establish their
ability to affect ethanol intake. Ivermectin (IVM), in particular,
is being investigated for its ability to reduce ethanol intake in pre-
clinical studies and in a developing clinical trial, due to its selective
modulation of P2X4Rs within the P2XR superfamily.
IVM AS A POTENTIAL CLINICAL TOOL FOR TREATMENT OF
AUDs; INSIGHTS FROM P2X4Rs
IVM is an FDA-approved semi-synthetic macrocyclic lactone
avermectin used in veterinary and clinical medicine (Richard-
Lenoble et al., 2003; Geary, 2005; Fox, 2006; Gonzalez et al.,
2012). As an anti-parasitic agent, IVM has been administered
to millions of humans, with few reports of severe adverse side
effects (Guzzo et al., 2002; Omura, 2008). Its positive safety pro-
file has been echoed in clinical reports at doses up to 10 times the
recommended levels (Guzzo et al., 2002).
IVM’s utility as an antihelminthic agent generally is attributed
to its ability to potentiate non-mammalian glutamate-gated
inhibitory chloride channels (Cully et al., 1994; Dent et al., 1997).
In mammals, IVM acts at a number of ion channels including
GABAARs and GlyRs (for review see Dawson et al., 2000; Shan
et al., 2001) and this action is thought to produce anticonvulsant
effects in mice (Dawson et al., 2000). Despite robust findings that
IVM enhances inhibitory neurotransmission and decreases exci-
tatory transmission (e.g., Shan et al., 2001; Ikeda, 2003), evidence
suggests that IVM blocks some of the behavioral effects of GABA
agonists (Davies et al., 2013). IVM also has been found to act as
a selective, positive allosteric modulator of ATP-evoked currents
at P2X4Rs (Khakh et al., 1999; Priel and Silberberg, 2004; Lalo
et al., 2007). Further sections of this review present pharmacolog-
ical and pre-clinical evidence suggesting that IVM may serve as a
useful clinical tool for the treatment of AUDs.
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IVM ANTAGONIZES THE INHIBITORY EFFECTS OF ETHANOL
ON P2X4Rs BY ACTING ON COMMON SITES IN P2X4Rs
Previous reports suggested that IVM binds at the lipid–protein
interface, acting at sites located within the TM segment and at the
ectodomain-TM interface of the P2X4R (Jelinkova et al., 2006,
2008; Silberberg et al., 2007). Based on the similar structural
loci for ethanol and IVM action in P2X4Rs, later studies were
performed to test whether IVM would interfere and reduce the
effect of ethanol on P2X4Rs. Using a Xenopus oocyte expres-
sion system and two-electrode voltage clamp, these studies were
the first to demonstrate that IVM antagonized ethanol effects in
P2X4Rs in a concentration-dependent manner (Asatryan et al.,
2010). Importantly, 0.5μM IVM eliminated the inhibitory effect
of pharmacologically relevant concentrations of ethanol (25,
50mM) without evidence of causing potentiation in P2X4Rs. In
addition, these studies revealed that the interaction is competitive
in nature; suggesting that the drugs have a common molecular
target/site(s) in P2X4Rs. Consistent with the latter notion, fur-
ther studies found that Met336 at the ectodomain-TM2 interface
and Trp46 in the TM1 segment played a role in the action of both
drugs. Mutations at position 336, which were known to alter the
sensitivity of P2X4Rs to ethanol (Popova et al., 2010), also altered
the receptor’s sensitivity to IVM (Asatryan et al., 2010; Popova
et al., 2013). Moreover, the physico-chemical requirements for
the residue at this site were similar for the actions of both drugs.
Specifically, the hydrophobic side chain ofMet336 played a critical
role in governing the actions of ethanol and IVM. At position 46,
substitution of non-aromatic residues reduced the effect caused
by ethanol concentrations that were greater than 50mM and
shifted IVM response from potentiation to inhibition (Popova
et al., 2013). Furthermore, the findings from the double mutant
W46A–M336A P2X4Rs suggested an important role of the Trp46
and Met336 interaction for ethanol and IVM action. Similar
to the effects in the single mutants (W46A and M336A), there
was: (1) reduced response to ethanol and (2) a shift of the IVM
response similar to the effect found with non-aromatic mutants at
position 46. Collectively, the findings supported the notions that
positions 46 and 336 are common sites for the actions of IVM,
serving as sites for the antagonistic effect of IVM. Importantly,
the interaction between residues at these positions contributes to
the putative binding pocket for both drugs. The presence of this
pocket was supported by molecular modeling studies.
MOLECULAR MODELING REVEALS A PUTATIVE BINDING
POCKET FOR ETHANOL AND IVM IN P2X4Rs
To visualize residues experimentally found to be important for
ethanol and IVM action (Met336 and Trp46) and verify possible
interactions between these and other residues, molecular model-
ing approach was applied. The first homology model of rat P2X4
was built using as a template the zebrafish P2X4 3.1 Å resolu-
tion crystal structure in the closed state published in 2009 by the
Gouaux group (Kawate et al., 2009). This model revealed a pocket
formed by Asp331, Met336, Trp46, and Trp50 that was suggested
to play a role in the actions of ethanol and IVM. It was demon-
strated that the Trp46 and Trp50 side chains of the first alpha
helix face Asp331 and Met336 in the final alpha-helix of the adja-
cent subunit (Figure 2). A site was formed by manual rotations
of the C-alpha to C-beta bonds of Trp46 and Trp50 in which
the two Trp side chains and the sulfur of Met336 interact. An
ethanol molecule was fitted manually in the site while considering
a combination of cation-Pi interactions between the hydrogen of
ethanol and the tryptophans and additional interactions between
the methionine sulfur atom and the oxygen atom of ethanol. This
first model of P2X4Rs revealed that several amino acid residues
known to be important for the effects of ethanol on these recep-
tors, although seemingly widely scattered in the primary sequence
of P2X4R, were actually clustered around a small cavity in the
three-dimensional structure.
The molecular model was revised later in the light of the new
open state crystal structure of the zebrafish P2X4R (Hattori and
Gouaux, 2012) and new findings on ethanol and IVM binding
(Popova et al., 2013). It provided insights into the role of the
molecular interactions in the responses to ethanol and IVM. The
model supported the previous one confirming that there is a
binding pocket in P2X4Rs formed by positions 46, 331, and 336.
In addition, position 42 was added to the residues that play a role
in the formation of the pocket and further experimental work
supported that finding. This model also confirmed that Trp46 and
Met336 face each other (Asatryan et al., 2010). It was proposed
that interactions between the aromatic rings and sulfur groups
may occur in number of ways; including hydrogen bonding to the
aryl hydrogens, SH–Pi interactions, electrostatic, or hydrophobic
interactions (Tatko and Waters, 2004). Importantly, interactions
of the sulfur atom of methionine with multiple aromatic groups
can produce “hot spots” in protein–protein interactions (Ma and
Nussinov, 2007) contributing to the stabilization of the protein
(Tatko and Waters, 2004).
Aromatic residues located within the upper part of the TM1
segment of P2X4Rs, such as Tyr42, Trp46 and Trp50, have been
suggested to play a role in the three-dimensional organization of
the receptor through Pi-Pi interactions (Jelinkova et al., 2008).
The model in Figure 2 demonstrated that Trp46 is “sandwiched”
between Tyr42 and Trp50 (Popova et al., 2013). Interestingly, dis-
ruption of the Pi-Pi interactions between Trp46 and Tyr42 but
not Trp46 and Trp50 seemed to alter ethanol and IVM responses.
Formation of the hydrogen bond between the phenolic hydroxyl
group of Tyr 42 and hydroxyl oxygen of IVM also were deemed
to be important for IVM binding. Substituting Tyr42 for Phe,
which lacks the hydroxyl group on the aromatic ring, signifi-
cantly altered ethanol and IVM responses (Popova et al., 2013).
These findings suggest the importance of Tyr42 in themodulation
induced by the two drugs.
The new model also provided insights into the binding of the
IVM molecule in the identified putative binding site. The model
replicated the vertical and lateral positions of IVM in the X-ray
structure of the pentameric glutamate-gated chloride ion chan-
nel GluCl (Hibbs and Gouaux, 2011). The van der Waals surface
of IVM molecule fit well within one of the 39 cavities found in
P2X4Rmodel.Molecular dynamic simulations demonstrated that
the IVM molecule was stable in that position. The sites identi-
fied thus far as important for the action of IVM in P2X4Rs are
located close to fenestrations that were described recently at the
membrane interface of P2X4Rs (Samways et al., 2012; Jiang et al.,
2013). In the open state of the receptor, these “lateral portals”
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FIGURE 2 | Full size and zoomed models of the rat P2X4R.
A homology model of rat P2X4R was built by threading the rat primary
sequence on the zebrafish X-ray structure in the open conformation (PDB
ID 4DW1) (Hattori and Gouaux, 2012), essentially as described before
(Popova et al., 2013). (A) A side view of the full P2X4R as viewed in the
plane of the membrane looking toward the ion pore from the outside.
Horizontal lines indicate the predicted extent of the membrane bilayer.
The ATP binding site is over 20 Angstroms distant from the IVM binding
site, yet there is substantial interaction between them. Residues
important for IVM binding are rendered with space filling surfaces
(carbon, oxygen, nitrogen, and hydrogen are colored gray, red, blue, and
white). IVM is rendered in ball and stick and surrounded by a transparent
yellow surface to outline possible interactions with the protein. A
putative EtOH binding site, based on the mutations, is indicated by an
arrow (EtOH site). (B) The IVM binding site is zoomed to reveal details
about interactions with residues identified as important by mutagenesis.
Abbreviation: P2X4R, purinergic P2X4 receptor; ATP, adenosine
5′-triphosphate; IVM, ivermectin; EtOH, ethanol.
open to approximately 8 Å (Jiang et al., 2013) which is sufficient
for the IVM binding. Consistent with the latter, IVM is known to
bind and stabilize the open state conformation of the receptor.
Taken together, the molecular models built on the closed and
open state zebrafish P2X4R structure suggested for the first time
the presence of nearly co-localized sites in an ethanol and IVM
action pocket in P2X4Rs formed by amino acid residues at posi-
tions 42, 46, 331, and 336 (Asatryan et al., 2010). This action
pocket represents a potential target for development of medica-
tion to treat AUDs. Moreover, growing evidence suggests that the
interactions of ethanol and IVM apparent in molecular models
may be indicative of IVM’s efficacy to regulate ethanol-related
behaviors, including consumption.
BEHAVIORAL PHARMACOLOGICAL EVIDENCE FOR THE
ANTI-ETHANOL EFFECTS OF IVM
In addition to direct actions at P2X4Rs and in line with some
P2X4R functions, IVM likely affects several neural signaling sys-
tems that are modulated by P2X4Rs and have been reported to
be involved in alcohol drinking, such as GABA, glutamate, and
dopamine (Xiao et al., 2008; Vavra et al., 2011). Further, IVM
independently affects several neural systems associated with alco-
hol drinking. For example, IVM potentiates activation of GlyRs
(Lynagh et al., 2011; Wang and Lynch, 2012), which have been
identified as one of a few known primary targets for alcohol (cf.
Vengeliene et al., 2008). In addition, IVM enhances α7 nAChR
function (cf. Daly, 2005), which is pertinent due to the inhibiting
actions of alcohol on these receptor subtypes (cf. Davis and de
Fiebre, 2006).
Converging pre-clinical evidence suggests that a single sys-
temic IVM exposure reduces alcohol intake and reinforcement
under binge-like and 24-h choice drinking conditions in male
and female mice and during a 3-h operant session in male
rats (Kosten, 2011; Yardley et al., 2012; Asatryan et al., 2014).
These studies suggest that acute IVM administration is effective
at reducing ethanol intake, despite its low CNS accumulation
(Yardley et al., 2012; Asatryan et al., 2014). In addition, this work
found that IVM-induced reductions in ethanol intake were pro-
portional to detectable central IVM levels (Yardley et al., 2012).
The estimated times to maximal CNS IVM levels have ranged
from 2–5 (Borst and Schinkel, 1996) to 8–10 h (Yardley et al.,
2012; Asatryan et al., 2014). This low CNS accumulation is cou-
pled with a lengthy clearance period (plasma half-life: 12.67 h;
brain half-life: 19 h) (Asatryan et al., 2014). Interestingly, Yardley
et al. (2012) reported that 7-day repeated peripheral adminis-
tration with a sub-threshold (1.25mg/kg) dose of IVM reduced
ethanol intake in C57BL/6 mice under sub-chronic 24-h con-
tinuous access conditions. This additive effect of dosing likely is
related to the slow clearance of the medication from the system.
The LD(50) for IVM has been reported to range from approx-
imately 18 to 50mg/kg depending upon the subjects’ sex and
species (Dadarkar et al., 2007; Trailovic and Varagic, 2007), which
far exceeds the reported therapeutic dose levels for reduction of
ethanol intake and reinforcement (2.5–10mg/kg) (Kosten, 2011;
Yardley et al., 2012; Asatryan et al., 2014). However, doses as low
as 10mg/kg have been reported to induce CNS toxicity (Lerchner
et al., 2007). Despite these reports, evidence suggests that IVM is
well-tolerated, and elicits few adverse effects (Davis et al., 1999;
www.frontiersin.org June 2014 | Volume 8 | Article 176 | 7
Franklin et al. P2X4Rs, IVM, and AUDs
Omura, 2008; Sun et al., 2010) in the absence of a P-glycoprotein
(P-gp) deficiency (Lankas et al., 1997).
As a result of IVM’s pharmacokinetic characteristics, it is
possible that some effects of the compound reflect locomotor
alterations. Free-choice oral IVM self-administration may stim-
ulate activity at low concentrations in some mouse strains (Davis
et al., 1999). In contrast, i.p. IVM was reported to depress loco-
motor behaviors in rats, with a threshold dose between 0.5 and
1.0mg/kg (Spinosa et al., 2002). Systemic IVM injections have
been reported to induce motor deficits, such as somnolence and
ataxia, although these effects are largely dose-dependent (Spinosa
et al., 2002; Dadarkar et al., 2007; Trailovic and Varagic, 2007;
Kosten, 2011; Trailovic et al., 2011). Importantly, evidence sug-
gests that co-administration of alcoholic beverages with IVM
(Shu et al., 2000) or the use of ethanol as a dissolution medium
for IVM (Edwards et al., 1988) increases the bioavailability of
the compound, possibly resulting in potentiated locomotor dis-
ruptions (Shu et al., 2000). Thus, the viable therapeutic dose
window for IVM may require reassessment when administering
the compound to alcohol-drinking individuals.
INVOLVEMENT OF P2X4Rs IN THE ETHANOL ANTAGONIZING
(OR ANTI-ETHANOL) EFFECTS OF IVM
Accumulating evidence suggests that IVM may represent a phar-
macological tool to investigate the role of P2X4Rs in alcohol
drinking. Studies from P2X4-KO mice provided some insights
into the role of P2X4Rs in IVM’s anti-ethanol effects in vivo.
These studies found a significantly smaller potential of IVM to
reduce ethanol intake and ethanol preference in P2X4-KO vs. WT
mice using a 24-h two-bottle choice drinking paradigm (Wyatt
et al., 2014). This finding, in conjunction with previous IVM
measures (Bortolato et al., 2013) suggests that a significant por-
tion of IVM’s ability to reduce alcohol intake is linked to P2X4Rs
(Wyatt et al., 2014). The reduced ability of IVM to inhibit ethanol
consumption in P2X4-KO mice may also be linked, in part, to
changes in the compensatory alterations in the expression profile
of LGICs functionally associated with the regulation of ethanol
behaviors. Consistent with this notion, the work found significant
changes in the expression of α1 subunit of GABAARs in several
brain regions of P2X4-KO mice (Wyatt et al., 2014).
USING IVM AS A PLATFORM TO DEVELOP MORE EFFICIENT
MEDICATIONS FOR ALCOHOL USE DISORDERS
As described above, pre-clinical evidence has demonstrated the
ability of IVM to reduce ethanol consumption. However, this
effect is somewhat limited in magnitude (e.g., Yardley et al.,
2012). Despite its lipophilic nature, IVM does not readily achieve
high brain concentration, most likely because it is a good sub-
strate for the P-gp transporter. At the present time, there is an
ongoing effort to identify and/or develop new compounds that
enhances IVM’s retention in the CNS while maintaining its abil-
ity to reduce alcohol intake and maintain its high tolerability and
broad safety profile. It is thought that modification of the IVM
structure to reduce its P-gp substrate recognition (Lespine et al.,
2007; Menez et al., 2012) and alteration of its interaction with a
targeted brain receptor should positively impact the drug’s abil-
ity to reduce ethanol intake (Asatryan et al., 2014). Support for
this notion comes from recent work comparing the effects of IVM
with two IVM-related macrocyclic lactones, abamectin (ABM)
and selamectin (SEL), for their abilities to cross blood brain
barrier (BBB); reduce ethanol intake in mice; and to alter mod-
ulation of GABAARs and P2X4Rs expressed in Xenopus oocytes
(Asatryan et al., 2014). Interestingly, SEL, despite having a 50X
plus higher concentration in the brain (compared to IVM), dis-
played minimal ability to reduce ethanol intake in mice in a 24 h
two-bottle choice paradigm and was minimally effective in antag-
onizing the effects of ethanol in recombinant P2X4Rs (Asatryan
et al., 2014). ABM’s brain retention was significantly increased
compared to IVM; however, its effects on alcohol intake were
comparable to IVM. All three compounds were effective in mod-
ulating GABAARs. Collectively, this work suggested that chemical
structure and effects on receptor function are important for the
ability of avermectins to reduce ethanol intake and that these fac-
tors are more important than BBB penetration alone (Asatryan
et al., 2014).
Taken together, these findings support the hypothesis that
avermectins can be used as a platform for developing novel drugs
to prevent and/or treat AUDs. The findings also suggest that key
structure-activity relationships can be used to improve the ability
of avermectins to cross the blood brain barrier, while maintain-
ing their effects on P2X4Rs, thus improving their ability to reduce
ethanol intake.
CONCLUSIONS
P2X4Rs represent a novel and largely unexplored target for drug
development to prevent and/or treat AUDs. This hypothesis stems
from a large body of evidence indicating that P2X4Rs play a role in
modulation and/or regulation of ethanol intake and that there is
an inverse relationship between P2X4R activity and ethanol con-
sumption. Further support for this hypothesis can be taken from
the recent finding that IVM, a positive modulator of P2X4Rs,
antagonizes ethanol-mediated inhibition of P2X4Rs in vitro and
reduces ethanol intake and operant ethanol self-administration in
rodents. Notably, the findings, to date, support developing novel
therapeutic agents for AUDs that focus on this largely unexplored
target. To support this endeavor, ongoing and future studies will
continue assessing the role of P2X4Rs in reward systems linked
to alcohol intake, which should provide new insights regarding
ethanol-mediated molecular cascades. Findings from the cur-
rent review also support the ongoing use of IVM as a platform
for developing new chemical entities that target P2X4Rs for the
treatment of AUDs.
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